Protein modification systems as cancer biomarkers and therapeutic targets

Abstract

Protein post-translational modifications (PTMs), such as acetylation, lactylation, methylation, phosphorylation, ubiquitination, and glycosylation, play central roles in regulating diverse cellular processes, including signal transduction, metabolic adaptation, chromatin organization, and proteostasis. In cancer, PTM networks are extensively rewired, with profound alterations in enzyme levels, protein modification landscapes, and crosstalk among different modification types. These changes collectively shape key cancer hallmarks, such as sustained proliferative signaling, immune evasion, and therapeutic resistance. Recent advances in proteomic technologies have enabled comprehensive mapping of PTM landscapes and their regulatory mechanisms, facilitating the identification of PTM signatures associated with tumor subtyping, disease progression, and treatment response. This review summarized biomarkers and therapeutic targets associated with dysregulated PTM regulatory pathways in cancer.

Keywords

protein modifications / cancer / biomarker / therapeutic target / precision medicine

References

[1] Geffen Y, Anand S, Akiyama Y et al. Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation. Cell 2023; 186:3945-67. https://doi.org/10.1016/j.cell.2023.07.013

[2] Zhong Q, Xiao X, Qiu Y et al. Protein posttranslational modifications in health and diseases: functions, regulatory mechanisms, and therapeutic implications. MedComm 2023; 4:e261. https://doi.org/10.1002/mco2.261

[3] Ling Y, Cai F, Su T et al. Glycosylation in kidney diseases. Precis Clin Med 2025; 8:pbaf017. https://doi.org/10.1093/pcmedi/pbaf017

[4] Woodsmith J, Kamburov A, Stelzl U. Dual coordination of post translational modifications in human protein networks. PLoS Comput Biol 2013; 9:e1002933. https://doi.org/10.1371/journal.pcbi.1002933

[5] Li W, Li F, Zhang X et al. Insights into the post-translational modification and its emerging role in shaping the tumor microenvironment. Sig Transduct Target Ther 2021; 6:422. https://doi.org/10.1038/s41392-021-00825-8

[6] Bahar ME, Kim HJ, Kim DR. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. Sig Transduct Target Ther 2023; 8:455. https://doi.org/10.1038/s41392-023-01705-z

[7] Seeler J-S, Dejean A. SUMO and the robustness of cancer. Nat Rev Cancer 2017; 17:184-97. https://doi.org/10.1038/nrc.2016.143

[8] Tomuleasa C, Tigu A-B, Munteanu R et al. Therapeutic advances of targeting receptor tyrosine kinases in cancer. Sig Transduct Target Ther 2024; 9:201. https://doi.org/10.1038/s41392-024-01899-w

[9] Li Y, Porta-Pardo E, Tokheim C et al. Pan-cancer proteogenomics connects oncogenic drivers to functional states. Cell 2023; 186:3921-44. https://doi.org/10.1016/j.cell.2023.07.014

[10] Klomp JE, Diehl JN, Klomp JA et al. Determining the ERKregulated phosphoproteome driving KRAS-mutant cancer. Science 2024; 384:eadk0850. https://doi.org/10.1126/science.adk0850

[11] Luchini C, Paolino G, Mattiolo P et al. KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. J Exp Clin Cancer Res 2020; 39:227. https://doi.org/10.1186/s13046-020-01732-6

[12] Bergholz JS, Wang Q, Wang Q et al. PI3K β controls immune evasion in PTEN-deficient breast tumours. Nature 2023; 617:139-46. https://doi.org/10.1038/s41586-023-05940-w

[13] Zhang R, Hu M, Liu Y et al. Integrative omics uncovers low tumorous magnesium content as a driver factor of colorectal cancer. Genomics Proteomics Bioinformatics 2024; 22:qzae053. https://doi.org/10.1093/gpbjnl/qzae053

[14] Gao L, Lu Y, Chen H-N et al. Deciphering the clinical significance and kinase functions of gsk3 α in colon cancer by proteomics and phosphoproteomics. Mol Cell Proteomics 2023; 22:100545. https://doi.org/10.1016/j.mcpro.2023.100545

[15] Zhang R, Hu M, Chen H-N et al. Phenotypic heterogeneity analysis of APC-mutant colon cancer by proteomics and phosphoproteomics identifies RAI 14 as a key prognostic determinant in East Asians and Westerners. Mol Cell Proteomics 2023; 22:100532. https://doi.org/10.1016/j.mcpro.2023.100532

[16] Wang X, Luo Y, He S et al. Age-, sex-and proximal-distalresolved multi-omics identifies regulators of intestinal aging in non-human primates. Nat Aging 2024; 4:414-33. https://doi.org/10.1038/s43587-024-00572-9

[17] Gong Y, Zhan H, Wei N et al. Acetylation profiling by Iseq-Kac reveals insights into HSC aging and lineage decision. Nat Chem Biol 2025; 21:1675-87. https://doi.org/10.1038/s41589-025-01916-1

[18] Li J, Huang S, Yuan F et al. Prognostic and immunotherapeutic response prediction in hepatocellular carcinoma: role of non-histone acetylation/deacetylation scoring. Discov Onc 2025; 16:1488. https://doi.org/10.1007/s12672-025-03339-9

[19] Lu X, Xu S, Deng Z et al. Molecular mechanisms and genetic features of cholangiocarcinoma: implications for targeted therapeutic strategies. Precis Clin Med 2025; 8:pbaf021. https://doi.org/10.1093/pcmedi/pbaf021

[20] Ji H, Zhou Y, Zhuang X et al. HDAC3 deficiency promotes liver cancer through a defect in H3K9ac/H3K9me3 transition. Cancer Res 2019; 79:3676-88. https://doi.org/10.1158/0008-5472.CAN-18-3767

[21] Sinha A, Saini KK, Chandramouli A et al. ACSL4-mediated H3K9 and H3K27 hyperacetylation upregulates SNAIL to drive TNBC metastasis. Proc Natl Acad Sci USA 2024; 121:e2408049121. https://doi.org/10.1073/pnas.2408049121

[22] Fan S W.-j. L, Qi Y et al. PRMT5 encourages cell migration and metastasis of tongue squamous cell carcinoma through methylating _Np63 α. Cell Death Differ 2026; 33:465-79. https://doi.org/10.1038/s41418-025-01575-8

[23] Wu Y, Xu X, Tong Y et al. Metformin impairs breast cancer growth through the inhibition of PRMT6. Adv Sci 2026; 13:e08525. https://doi.org/10.1002/advs.20250852524

[24] Akano I, Hebert JM, Tiedemann RL et al. The SWI/SNFrelated protein SMARCA3 is a histone H3K23 ubiquitin ligase that regulates H3K9me3 in cancer. Mol Cell 2025; 85:2885-99. https://doi.org/10.1016/j.molcel.2025.06.020

[25] Wang P, Qiu J, Fang Y et al. SENP3 inhibition suppresses hepatocellular carcinoma progression and improves the efficacy of anti-PD-1 immunotherapy. Cell Death Differ 2025; 32:959-72. https://doi.org/10.1038/s41418-024-01437-9

[26] Lu R-S, Ren L-K, Fei X-B et al. PSMD14-mediated LDHA deubiquitination upregulates ACLY expression via H3K18 lactylation to promote lipid synthesis and pancreatic cancer progression. Adv Sci 2025; 12:e05762. https://doi.org/10.1002/advs.202505762

[27] Loix M, Zelcer N, Bogie JFJ et al. The ubiquitous role of ubiquitination in lipid metabolism. Trends Cell Biol 2024; 34:416-29. https://doi.org/10.1016/j.tcb.2023.09.001

[28] Fang Y, Gu Y, Xu T et al. SENP1 drives glycolysis and cisplatin resistance in gastric cancer via desumoylating ENO1. J Exp Clin Cancer Res 2025; 44:285. https://doi.org/10.1186/s13046-025-03543-z

[29] Zhu Z, Sun J, Xu W et al. MGAT4A/galectin9-driven N -glycosylation aberration as a promoting mechanism for poor prognosis of endometrial cancer with TP 53 mutation. Adv Sci 2024; 11:2409764. https://doi.org/10.1002/advs.202409764

[30] Dong C, Zhang Y, Zeng J et al. FUT2 promotes colorectal cancer metastasis by reprogramming fatty acid metabolism via YAP/TAZ signaling and SREBP-1. Commun Biol 2024; 7:1297. https://doi.org/10.1038/s42003-024-06993-x

[31] Song J, Liu W, Wang J et al. GALNT6 promotes invasion and metastasis of human lung adenocarcinoma cells through O-glycosylating chaperone protein GRP78. Cell Death Dis 2020; 11:352. https://doi.org/10.1038/s41419-020-2537-6

[32] Tan Z, Jiang Y, Liang L et al. Dysregulation and prometastatic function of glycosyltransferase C1GALT 1 modulated by cHP1BP3/miR-1-3p axis in bladder cancer. J Exp Clin Cancer Res 2022; 41:228. https://doi.org/10.1186/s13046-022-02438-7

[33] Murata K, Miyoshi E, Kameyama M et al. Expression of Nacetylglucosaminyltransferase V in colorectal cancer correlates with metastasis and poor prognosis. Clin Cancer Res 2000; 6:1772-7.

[34] Yamamoto E, Ino K, Miyoshi E et al. Expression of Nacetylglucosaminyltransferase V in endometrial cancer correlates with poor prognosis. Br J Cancer 2007; 97:1538-44. https://doi.org/10.1038/sj.bjc.6604044

[35] Wang X, He H, Zhang H et al. Clinical and prognostic implications of β1, 6-N-acetylglucosaminyltransferase V in patients with gastric cancer. Cancer Sci 2013; 104:185-93. https://doi.org/10.1111/cas.12049

[36] Granovsky M, Fata J, Pawling J et al. Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nat Med 2000; 6:306-12. https://doi.org/10.1038/73163

[37] Wang Y, Zhang S, Bai J et al. SMAD4 palmitoylation drives a metabolic-transcriptional circuit to promote tumorigenesis and confers radiosensitivity in pancreatic cancer. Adv Sci 2026;e19791. https://doi.org/10.1002/advs.202519791

[38] Lin C, Li Z, Zhu X et al. Abnormal β-hydroxybutyrylation modification of ARG1 drives reprogramming of arginine metabolism to promote the progression of colorectal cancer. Adv Sci 2025; 12:e02402. https://doi.org/10.1002/advs.202502402

[39] Su J, Zhao M, Feng W et al. TAF1 acetyltransferase promotes colorectal carcinoma metastasis by catalyzing β- hydroxybutyrylation of KCTD9. Oncogene 2026; 45:87-103. https://doi.org/10.1038/s41388-025-03644-1

[40] Xie B, Zhang M, Li J et al. KAT8-catalyzed lactylation promotes eEF1A2-mediated protein synthesis and colorectal carcinogenesis. Proc Natl Acad Sci USA 2024; 121:e2314128121. https://doi.org/10.1073/pnas.2314128121

[41] Yang Z, Yan C, Ma J et al. Lactylome analysis suggests lactylation-dependent mechanisms of metabolic adaptation in hepatocellular carcinoma. Nat Metab 2023; 5:61-79. https://doi.org/10.1038/s42255-022-00710-w

[42] Wang X, Li Y, Tang Y et al. PD-L1 delactylation-promoted nuclear translocation accelerates liver cancer growth through elevating SQLE transcription activity. Cancer Lett 2025; 630:217901. https://doi.org/10.1016/j.canlet.2025.217901

[43] Pitter MR, Kryczek I, Zhang H et al. PAD4 controls tumor immunity via restraining the MHC class II machinery in macrophages. Cell Rep 2024; 43:113942. https://doi.org/10.1016/j.celrep.2024.113942

[44] Yan Y, Yu J, Wang W et al. Palmitoylation prevents B7-H4 lysosomal degradation sustaining tumor immune evasion. Nat Commun 2025; 16:4254. https://doi.org/10.1038/s41467-025-58552-5

[45] Xia Z, Gao L, Hu M et al. Comparative N -glycoproteomics reveals subtype-specific N -glycosylation signatures and immune associations in cholangiocarcinoma. Mol Cell Proteomics 2025; 24:101084. https://doi.org/10.1016/j.mcpro.2025.101084

[46] Park MS, Yang AY, Lee JE et al. GALNT3 suppresses lung cancer by inhibiting myeloid-derived suppressor cell infiltration and angiogenesis in a TNFR and c-MET pathway-dependent manner. Cancer Lett 2021; 521:294-307. https://doi.org/10.1016/j.canlet.2021.08.015

[47] She X, Lan J, Zhang H et al. METTL 3 methylation induces decay of endogenous retroelement transcripts to promote tumor immune evasion. Cancer Res 2026. https://doi.org/10.1158/0008-5472.CAN-25-2893

[48] Xue T, Liu X, Song C et al. Citrullination of AKT2 catalyzed by PAD1 facilitates the maintenance of stemness characteristics of ovarian cancer stem-like cells in ovarian cancer. Adv Sci 2025; 12:e01014. https://doi.org/10.1002/advs.202501014

[49] Shao S, Li W, Hong Y et al. ZDHHC2-dependent palmitoylation dictates ferroptosis and castration sensitivity in prostate cancer via controlling ACSL4 degradation and lipid peroxidation. Adv Sci 2026; 13:e14077. https://doi.org/10.1002/advs.202514077

[50] Deng H, Xu Q, Zhang Q et al. EZH2 promotes chemoresistance in colorectal cancer by inhibiting autophagy through NRP1 suppression. Biochem J 2025; 482:569-81. https://doi.org/10.1042/BCJ20240607

[51] Zhang Q, Shi Y, Liu S et al. EZH2/G9a interact to mediate drug resistance in non-small-cell lung cancer by regulating the SMAD4/ERK/c-Myc signaling axis. Cell Rep 2024; 43:113714. https://doi.org/10.1016/j.celrep.2024.113714

[52] Wang X, Su Y, Lan B et al. USP22 promotes the proliferation and sorafenib resistance of hepatocellular carcinoma cells via its deubiquitinase activity. Clin Transl Med 2025; 15:e70324. https://doi.org/10.1002/ctm2.70324

[53] Zhang H, Han B, Lu H et al. USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma. Cancer Lett 2018; 433:186-98. https://doi.org/10.1016/j.canlet.2018.07.002

[54] Wang H-L, Chen Y, Wang Y-Q et al. Sirtuin5 protects colorectal cancer from DNA damage by keeping nucleotide availability. Nat Commun 2022; 13:6121. https://doi.org/10.1038/s41467-022-33903-8

[55] He Y, Zheng C-C, Yang J et al. Lysine butyrylation of HSP90 regulated by KAT8 and HDAC11 confers chemoresistance. Cell Discov 2023; 9:74. https://doi.org/10.1038/s41421-023-00570-y

[56] Gao C, Chen G, Romero G et al. Induction of Gsk3 β-β-TrCP interaction is required for late phase stabilization of β-catenin in canonical Wnt signaling. J Biol Chem 2014; 289:7099-108. https://doi.org/10.1074/jbc.M113.532606

[57] Xuan Z, Chen C, Sun H et al. NDR1/FBXO11 promotes phosphorylation-mediated ubiquitination of β-catenin to suppress metastasis in prostate cancer. Int J Biol Sci 2024; 20:4957-77. https://doi.org/10.7150/ijbs.98907

[58] Hino S-i, Tanji C, Nakayama KI et al. Phosphorylation of β-catenin by cyclic AMP-dependent protein kinase stabilizes β-catenin through inhibition of its ubiquitination. Mol Cell Biol 2005; 25:9063-72. https://doi.org/10.1128/MCB.25.20.9063-9072.2005

[59] Li Y, Zhao L, Deng J et al. PLK1 stabilizes β-catenin to drive colorectal carcinogenesis through NFKB2-mediated transcriptional activation of USP2a and site-specific phosphorylation. Theranostics 2026; 16:3488-506. https://doi.org/10.7150/thno.122368

[60] He Y-m, Zhou X-m, Jiang S-y et al. TRIM25 activates AKT/mTOR by inhibiting PTEN via K63-linked polyubiquitination in non-small cell lung cancer. Acta Pharmacol Sin 2022; 43:681-91. https://doi.org/10.1038/s41401-021-00662-z

[61] Quan Z, Peng B, Hu K et al. AP5Z1 affec t s hepatocellular carcinoma growth and autophagy by regulating PTEN ubiquitination and modulating the PI3K/Akt/mTOR pathway. J Transl Med 2025; 23:564. https://doi.org/10.1186/s12967-025-06537-9

[62] Jiang Q, Song P, Zhang S et al. TRIM21 and OTUD6A orchestrate AKT K27-linked atypical ubiquitination to modulate cancer chemoresistance. Nat Struct Mol Biol 2026; 33:84-99. https://doi.org/10.1038/s41594-025-01697-0

[63] Yan Y, Zhou S, Chen X et al. Suppression of ITPKB degradation by Trim25 confers TMZ resistance in glioblastoma through ROS homeostasis. Sig Transduct Target Ther 2024; 9:58. https://doi.org/10.1038/s41392-024-01763-x

[64] Huang B, Jin M, Cui G et al. GCN5-ERK lactylation-phosphorylation loop amplifies lactate-driven cancer progression. Nat Chem Biol 2026; 22:634-48. https://doi.org/10.1038/s41589-025-02107-8

[65] Yuan Q, Shi Y, Wang J et al. p38 mediated ACSL4 phosphorylation drives stress-induced esophageal squamous cell carcinoma growth through Src myristoylation. Nat Commun 2025; 16:3319. https://doi.org/10.1038/s41467-025-58342-z

[66] Liu Y, Su Z, Tavana O et al. Understanding the complexity of p53 in a new era of tumor suppression. Cancer Cell 2024; 42:946-67. https://doi.org/10.1016/j.ccell.2024.04.009

[67] Mo Y, Han Y, Chen Y et al. ZDHHC20 mediated Spalmitoylation of fatty acid synthase (FASN) promotes hepatocarcinogenesis. Mol Cancer 2024; 23:274. https://doi.org/10.1186/s12943-024-02195-5

[68] Zhu Y, Gu L, Lin X et al. Dynamic regulation of ME1 phosphorylation and acetylation affects lipid metabolism and colorectal tumorigenesis. Mol Cell 2020; 77:138-49. https://doi.org/10.1016/j.molcel.2019.10.015

[69] Tong Y, Guo D, Lin S-H et al. SUCLA2-coupled regulation of GLS succinylation and activity counteracts oxidative stress in tumor cells. Mol Cell 2021; 81:2303-16. https://doi.org/10.1016/j.molcel.2021.04.002

[70] Chen X, Ke Z, Wei S et al. ASCT2 palmitoylation regulated by JNK1-ZDHHC14 axis orchestrates glutamine metabolism and NSCLC progression. Cell Discov 2026; 12:13. https://doi.org/10.1038/s41421-026-00870-z

[71] Lu B, Qiu R, Wei J et al. Phase separation of phospho-HDAC6 drives aberrant chromatin architecture in triple-negative breast cancer. Nat Cancer 2024; 5:1622-40. https://doi.org/10.1038/s43018-024-00816-y

[72] Li Z, Lu X, Liu Y et al. Gain of LINC00624 enhances liver cancer progression by disrupting the histone deacetylase 6/tripartite motif containing 28/zinc finger protein 354C corepressor complex. Hepatology 2021; 73:1764-82. https://doi.org/10.1002/hep.31530

[73] Wang M, Mu G, Qiu B et al. Competitive antagonism of KAT7 crotonylation against acetylation affects procentriole formation and colorectal tumorigenesis. Nat Commun 2025; 16:2379. https://doi.org/10.1038/s41467-025-57546-7

[74] Wang Y, Zhou R, Zeng X et al. CLOCK-catalyzed histone H3K37 glutarylation suppresses H3K36 trimethylation pathways in glioblastoma. Sci Adv 2026; 12:eaea1127. https://doi.org/10.1126/sciadv.aea1127

[75] Zhao W, Wang G, Wang P et al. Arginine methylationdependent stabilization of SUV39H1 promotes breast cancer growth. Oncogene 2026; 45:1220-33. https://doi.org/10.1038/s41388-026-03712-0

[76] Qiu W, Wang B, Gao Y et al. Targeting histone deacetylase 6 reprograms interleukin-17-producing helper T cell pathogenicity and facilitates immunotherapies for hepatocellular carcinoma. Hepatology 2020; 71:1967-87. https://doi.org/10.1002/hep.30960

[77] Wang K, Chen X, Lin P et al. CD147-K148me2-driven tumor cell-macrophage crosstalk provokes NSCLC immunosuppression via the CCL5/CCR5 axis. Adv Sci 2024; 11:2400611. https://doi.org/10.1002/advs.202400611

[78] Xiao X, Shi J, He C et al. ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy. Nat Commun 2023; 14:2859. https://doi.org/10.1038/s41467-023-38605-3

[79] Li C-W, Lim S-O, Xia W et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun 2016; 7:12632. https://doi.org/10.1038/ncomms12632

[80] Zhu W, Fan C, Hou Y et al. Lactylation in tumor microenvironment and immunotherapy resistance: new mechanisms and challenges. Cancer Lett 2025; 627:217835. https://doi.org/10.1016/j.canlet.2025.217835

[81] Choi J, Kim GA, Han S et al. Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma. Hepatology 2019; 69:1983-94. https://doi.org/10.1002/hep.30233

[82] Zhao Y, Zhang L, Huo L et al. Clinical significance of fucosylated GP73 in the differ ential diagnosis of hepatocellular carcinoma. Int J Biol Markers 2018; 33:439-46. https://doi.org/10.1177/1724600818796646

[83] Warden DW, Ondrejka S, Lin J et al. Phospho- ERKTHR202/Tyr214 is overexpressed in hairy cell leukemia and is a useful diagnostic marker in bone marrow trephine sections. Am J Surg Pathol 2013; 37:305-8. https://doi.org/10.1097/PAS.0b013e3182712481

[84] Zhu L, Xu Y, Kang S et al. Quantification-promoted discovery of glycosylated exosomal PD-L1 as a potential tumor biomarker. Small Methods 2022; 6:2200549. https://doi.org/10.1002/smtd.202200549

[85] Kaufman B, Abu-Ahmad M, Radinsky O et al. Nglycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1. Mol Cancer 2025; 24:140. https://doi.org/10.1186/s12943-025-02330-w

[86] Li Y, Fu B, Wang M et al. Urinary extracellular vesicle Nglycomics identifies diagnostic glycosignatures for bladder cancer. Nat Commun 2025; 16:2292. https://doi.org/10.1038/s41467-025-57633-9

[87] Chen S, Li Y, Hu J et al. Integrating bulk RNA-seq, scRNAseq, and spatial transcriptomics data to identify novel posttranslational modification-related molecular subtypes and therapeutic responses in hepatocellular carcinoma. Cancer Cell Int 2025; 25:330. https://doi.org/10.1186/s12935-025-03964-y

[88] Liu J, Zhu X, Zha C et al. Succinylation heterogeneity in lung adenocarcinoma: from prognostic model to KLK6- driven tumor microenvironment remodeling. Front Immunol 2025; 16:1718994. https://doi.org/10.3389/fimmu.2025.1718994

[89] Zhang P, Wang D, Zhou G et al. Novel post-translational modification learning signature reveals B4GALT2 as an immune exclusion regulator in lung adenocarcinoma. J Immunother Cancer 2025; 13:e010787. https://doi.org/10.1136/jitc-2024-010787

[90] Sun Z, Yu L, Wu T et al. A lactylation-related gene signature predicts metastasis and prognosis in breast cancer. Sci Rep 2025; 15:42171. https://doi.org/10.1038/s41598-025-26165-z

[91] Chan A, Prassas I, Dimitromanolakis A et al. Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer. Clin Cancer Res 2014; 20:5787-95. https://doi.org/10.1158/1078-0432.Ccr-14-0289

[92] Mak LY, To WP, Wong DK et al. Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients. World J Gastroenterol 2019; 25:1398-408. https://doi.org/10.3748/wjg.v25.i11.1398

[93] Zhou JM, Wang T, Zhang KH. AFP-L3 for the diagnosis of early hepatocellular carcinoma: a meta-analysis. Medicine (Baltimore) 2021; 100:e27673. https://doi.org/10.1097/md.0000000000027673

[94] Funston G, Hamilton W, Abel G et al. The diagnostic performance of CA125 for the detection of ovarian and nonovarian cancer in primary care: a population-based cohort study. PLoS Med 2020; 17:e1003295. https://doi.org/10.1371/journal.pmed.1003295

[95] Guo J, Yu J, Song X et al. Serum CA125, CA199 and CEA combined detection for epithelial ovarian cancer diagnosis: a meta-analysis. Open Med 2017; 12:131-7. https://doi.org/10.1515/med-2017-0020

[96] Ferrer-Batallé M, Llop E, Ramírez M et al. Comparative study of blood-based biomarkers, α2,3-sialic acid PSA and PHI, for high-risk prostate cancer detection. Int J Mol Sci 2017; 18:845. https://doi.org/10.3390/ijms18040845

[97] Yang X, Yang Y, Li Z et al. Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis. PLoS One 2015; 10:e0124884. https://doi.org/10.1371/journal.pone.0124884

[98] Behrouzi R, Barr CE, Crosbie EJ. HE4 as a biomarker for endometrial cancer. Cancers 2021; 13:4764. https://doi.org/10.3390/cancers13194764

[99] Zhai G, Yang L, Luo Q et al. Evaluation of serum phosphopeptides as potential biomarkers of gastric cancer. RSC Adv 2017; 7:21630-7. https://doi.org/10.1039/C7RA00827A

[100] Khadjavi A, Mannu F, Destefanis P et al. Early diagnosis of bladder cancer through the detection of urinary tyrosinephosphorylated proteins. Br J Cancer 2015; 113:469-75. https://doi.org/10.1038/bjc.2015.232

[101] Lu J, Zhong F, Sun B et al. Diagnostic utility of serum Golgi phosphoprotein 3 in bladder cancer patients. Med Sci Monit 2019; 25:6736-41. https://doi.org/10.12659/msm.915950

[102] Wang T, Zhang K-H. New blood biomarkers for the diagnosis of AFP-negative hepatocellular carcinoma. Front Oncol 2020; 10:1316. https://doi.org/10.3389/fonc.2020.01316

[103] Yu H, Wang H, Dong W et al. The diagnostic and prognostic value of UBE2T in intrahepatic cholangiocarcinoma. PeerJ 2020; 8:e8454. https://doi.org/10.7717/peerj.8454

[104] Miao J, Liu Y, Zhao G et al. Feasibility of plasma-methylated SFRP2 for early detection of gastric cancer. Cancer Control 2020; 27:1073274820922559. https://doi.org/10.1177/1073274820922559

[105] Liu A, Li Y, Shen L et al. Clinical utility of serum fucosylated fraction of alpha-fetoprotein in the diagnostic of hepatocellular carcinoma: a comprehensive analysis with large sample size. Aging (Albany NY) 2022; 14: 2645-64. https://doi.org/10.18632/aging.203963

[106] Chan DW, Bruzek DJ, Oesterling JE et al. Prostate-specific antigen as a marker for prostatic cancer: a monoclonal and a polyclonal immunoassay compared. Clin Chem 1987; 33:1916-20. https://doi.org/10.1093/clinchem/33.10.1916

[107] Mcallister MJ, Mccall P, Dickson A et al. Androgen receptor phosphorylation at serine 81 and serine 213 in castrate-resistant prostate cancer. Prostate Cancer Prostatic Dis 2020; 23:596-606. https://doi.org/10.1038/s41391-020-0235-1

[108] Révillion F, Puech C, Rabenoelina F et al. Expression of the putative tumor suppressor gene PTPN13/PTPL 1 is an independent prognostic marker for overall survival in breast cancer. Intl J Cancer 2009; 124:638-43. https://doi.org/10.1002/ijc.23989

[109] Mcheik S, Aptecar L, Coopman P et al. Dual role of the PTPN13 tyrosine phosphatase in cancer. Biomolecules 2020; 10:1659. https://doi.org/10.3390/biom10121659

[110] Qin S, Chang F, Sun X et al. TRIM47 promotes hypopharyngeal and laryngeal cancers progression through promoting K63-linked ubiquitination of vimentin. Cancer Sci 2025; 116:367-80. https://doi.org/10.1111/cas.16397

[111] Zhang M, Yang B, Zhang L et al. TRIM27 is an adverse prognostic biomarker and associated with immune and molecular profiles in right-sided colon cancer. Am J Cancer Res 2022; 12:4988-5003.

[112] Shao W, Li J, Piao Q et al. FRMD3 inhibits the growth and metastasis of breast cancer through the ubiquitinationmediated degradation of vimentin and subsequent impairment of focal adhesion. Cell Death Dis 2023; 14:13. https://doi.org/10.1038/s41419-023-05552-2

[113] Qi M, Tu J, He R et al. NEDD4L suppresses proliferation and promotes apoptosis by ubiquitinating RAC2 expression and acts as a prognostic biomarker in clear cell renal cell carcinoma. Int J Mol Sci 2024; 25:11933. https://doi.org/10.3390/ijms252211933

[114] Xian W, Chen Y, Yu S et al. Ubiquitination and ALL: identifying FBXO8 as a prognostic biomarker and therapeutic target. Front Immunol 2025; 16:1554231. https://doi.org/10.3389/fimmu.2025.1554231

[115] Wang Z, Zhang W, Yin X et al. Multi-omics analyses were combined to construct ubiquitination-related features in colon adenocarcinoma and identify ASNS as a novel biomarker. Front Immunol 2024; 15:1466286. https://doi.org/10.3389/fimmu.2024.1466286

[116] Kitada S, Yamada S, Kuma A et al. Polypeptide Nacetylgalactosaminyl transferase 3 independently predicts high-grade tumours and poor prognosis in patients with renal cell carcinomas. Br J Cancer 2013; 109:472-81. https://doi.org/10.1038/bjc.2013.331

[117] Ishikawa M, Kitayama J, Nariko H et al. The expression pattern of UDP-N-Acetyl-α-D-galactosamine: polypeptide Nacetylgalactosaminyl transferase-3 in early gastric carcinoma. J Surg Oncol 2004; 86:28-33. https://doi.org/10.1002/jso.20042

[118] Wang H, Zheng J, Ma Q et al. GLT8D2 is a prognostic biomarker and regulator of immune cell infiltration in gastric cancer. Front Immunol 2024; 15:1370367. https://doi.org/10.3389/fimmu.2024.1370367

[119] Li Z, Yamada S, Inenaga S et al. Polypeptide Nacetylgalactosaminyltransferase 6 expression in pancreatic cancer is an independent prognostic factor indicating better overall survival. Br J Cancer 2011; 104:1882-9. https://doi.org/10.1038/bjc.2011.166

[120] Zhang Z, Cao Y, Zhao W et al. HDAC6 serves as a biomarker for the prognosis of patients with renal cell carcinoma. Cance Biomark 2017; 19:169-75. https://doi.org/10.3233/cbm-160298

[121] Jiang Y, Zhang J, Yu J et al. HDAC6 facilitates LUAD progression by inducing EMT and enhancing macrophage polarization towards the M2 phenotype. NPJ Precis Onc 2025; 9:150. https://doi.org/10.1038/s41698-025-00949-y

[122] Zeleke TZ, Pan Q, Chiuzan C et al. Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nat Cancer 2023; 4:257-75. https://doi.org/10.1038/s43018-022-00489-5

[123] Berger L, Kolben T, Meister S et al. Expression of H3K4me3 and H3K9ac in breast cancer. J Cancer Res Clin Oncol 2020; 146:2017-27. https://doi.org/10.1007/s00432-020-03265-z

[124] Zhen L, Gui-Lan L, Ping Y et al. The expression of H3K9Ac, H3K14Ac, and H4K20TriMe in epithelial ovarian tumors and the clinical significance. Int J Gynecol Cancer 2010; 20:82-6. https://doi.org/10.1111/IGC.0b013e3181ae3efa

[125] Ma Y, Chen M, Xu Z. Clinicopathological significance of AKT and phosphorylated AKT expression in hepatocellular carcinoma: a meta-analysis. BMC Cancer 2025; 25:1677. https://doi.org/10.1186/s12885-025-14948-6

[126] Guan L, Tang Y, Li G et al. Comprehensive analysis of role of cyclin-dependent kinases family members in colorectal cancer. Front Oncol 2022; 12:921710. https://doi.org/10.3389/fonc.2022.921710

[127] Liu X, Li M, Chen L et al. High expression of SHP2 predicts a promising prognosis in colorectal cancer. Indian J Pathol Microbiol 2024; 67:29-35. https://doi.org/10.4103/ijpm.ijpm_894_22

[128] Li G, Zhong Y, Shen Q et al. NEK2 serves as a prognostic biomarker for hepatocellular carcinoma. Int J Oncol 2017; 50:405-13. https://doi.org/10.3892/ijo.2017.3837

[129] Wu Y, Mohd Sani SB, Peng K et al. Research progress of the Otubains subfamily in hepatocellular carcinoma. Biomed Pharmacother 2024; 179:117348. https://doi.org/10.1016/j.biopha.2024.117348

[130] Xie H, He Y, Wu Y et al. Silencing of UBE2D1 inhibited cell migration in gastric cancer, decreasing ubiquitination of SMAD4. Infect Agents Cancer 2021; 16:63. https://doi.org/10.1186/s13027-021-00402-2

[131] Huang Y, Zou Y, Jie Z. RNF6 promotes the migration and invasion of breast cancer by promoting the ubiquitination and degradation of MST1. Exp Ther Med 2022; 23:118. https://doi.org/10.3892/etm.2021.11041

[132] Jia M, Guo Y, Lu X. USP33 is a biomarker of disease recurrence in papillary thyroid carcinoma. Cell Physiol Biochem 2018; 45:2044-53. https://doi.org/10.1159/000488041

[133] Yuan J, Xu B, Su Y et al. Identification of USP39 as a prognostic and predictive biomarker for determining the response to immunotherapy in pancreatic cancer. BMC Cancer 2025; 25:758. https://doi.org/10.1186/s12885-025-14096-x

[134] Fang H, Shi X, Gao J et al. TMEM209 promotes hepatocellular carcinoma progression by activating the Wnt/ β-catenin signaling pathway through KPNB1 stabilization. Cell Death Discov 2024; 10:438. https://doi.org/10.1038/s41420-024-02207-9

[135] Norman JS, Li PJ, Kotwani P et al. AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation. J Hepatol 2023; 79:1469-77. https://doi.org/10.1016/j.jhep.2023.08.020

[136] Natali PG, Nicotra MR, Bigotti A et al. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 1990; 45:457-61. https://doi.org/10.1002/ijc.2910450314

[137] Lakemeyer L, Sander S, Wittau M et al. Diagnostic and prognostic value of CEA and CA19- 9 in colorectal cancer. Diseases 2021; 9:21. https://doi.org/10.3390/diseases9010021

[138] Xu H, Huang K, Lin Y et al. Glycosyltransferase GLT8D1 and GLT8D2 serve as potential prognostic biomarkers correlated with tumor immunity in gastric cancer. BMC Med Genomics 2023; 16:123. https://doi.org/10.1186/s12920-023-01559-y

[139] Luo G, Jin K, Deng S et al. Roles of CA19-9 in pancreatic cancer: biomarker, predictor and promoter. Biochim Biophys Acta Rev Cancer 2021; 1875:188409. https://doi.org/10.1016/j.bbcan.2020.188409

[140] Azizian A, Rühlmann F, Krause T et al. CA19-9 for detecting recurrence of pancreatic cancer. Sci Rep 2020; 10:1332. https://doi.org/10.1038/s41598-020-57930-x

[141] Haugen BR, Alexander EK, Bible KC et al. 2015 american thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26:1-133. https://doi.org/10.1089/thy.2015.0020

[142] Li R, Wu X, Zhao P et al. A pan-cancer analysis identifies HDAC11 as an immunological and prognostic biomarker. FASEB J 2022; 36:e22326. https://doi.org/10.1096/fj.202101742RR

[143] Benard A, Goossens-Beumer IJ, Van Hoesel AQ et al. Nuclear expression of histone deacetylases and their histone modifications predicts clinical outcome in colorectal cancer. Histopathology 2015; 66:270-82. https://doi.org/10.1111/his.12534

[144] Hung SY, Lin HH, Yeh KT et al. Histone-modifying genes as biomarkers in hepatocellular carcinoma. Int J Clin Exp Pathol 2014; 7:2496-507.

[145] Dong R, Wang T, Dong W et al. TGM2-mediated histone serotonylation promotes HCC progression via MYC signalling pathway. J Hepatol 2025; 83:105-18. https://doi.org/10.1016/j.jhep.2024.12.038

[146] Hu M, Zhu C, Sun R et al. Low-input deep learning platform for citrullinated peptide identification, autoantigen discovery and rheumatoid arthritis treatment stratification. Nat Biomed Eng 2026. https://doi.org/10.1038/s41551-026-01628-4

[147] Tang KH, Li S, Khodadadi-Jamayran A et al. Combined inhibition of SHP2 and CXCR1/2 promotes antitumor T-cell response in NSCLC. Cancer Discov 2022; 12:47-61. https://doi.org/10.1158/2159-8290.CD-21-0369

[148] Kepp O, Semeraro M, Bravo-San Pedro JM et al. eIF2 α phosphorylation as a biomarker of immunogenic cell death. Semin Cancer Biol 2015; 33:86-92. https://doi.org/10.1016/j.semcancer.2015.02.004

[149] Bakkenist CJ, Beumer JH, Schmitz JC. ATM serine-1981 phosphorylation is a plausible biomarker. Cell Cycle 2015; 14:3207-8. https://doi.org/10.1080/15384101.2015.1084205

[150] Chen ZX, Mu MY, Yang G et al. Hypoxia-induced DTL promotes the proliferation, metastasis, and sorafenib resistance of hepatocellular carcinoma through ubiquitin-mediated degradation of SLTM and subsequent Notch pathway activation. Cell Death Dis 2024; 15:734. https://doi.org/10.1038/s41419-024-07089-4

[151] Han D, Wang L, Long L et al. The E3 ligase TRIM4 facilitates SET ubiquitin-mediated degradation to enhance ER-α action in breast cancer. Adv Sci 2022; 9:2201701. https://doi.org/10.1002/advs.202201701

[152] Wei J, Zhuang Y, Jiang C et al. Cohort-based pan-cancer analysis and experimental studies reveal ISG15 gene as a novel biomarker for prognosis and immunotherapy efficacy prediction. Cancer Immunol Immunother 2025; 74:168. https://doi.org/10.1007/s00262-025-04026-y

[153] Lee H-H, Wang Y-N, Xia W et al. Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1/PDL1 therapeutic efficacy. Cancer Cell 2019; 36:168-78. https://doi.org/10.1016/j.ccell.2019.06.008

[154] Lai Q-y, He Y-z, Peng X-w et al. Histone deacetylase 1 induced by neddylation inhibition contributes to drug resistance in acute myelogenous leukemia. Cell Commun Signal 2019; 17:86. https://doi.org/10.1186/s12964-019-0393-8

[155] Guan X, Liu R, Wang B et al. Inhibition of HDAC2 sensitises antitumour therapy by promoting NLRP3/GSDMDmediated pyroptosis in colorectal cancer. Clin Transl Med 2024; 14:e1692. https://doi.org/10.1002/ctm2.1692

[156] Fan X, Guo D, Li S et al. Fusidic acid reverses chemoresistance in breast cancer via targeting DDX6 to downregulate GSK-3 β/ β-catenin signaling. Adv Sci 2025; 12:e04680. https://doi.org/10.1002/advs.202504680

[157] Antonarakis ES, Lu C, Luber B et al. Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castrationresistant prostate cancer treated with first-and second-line abiraterone and enzalutamide. J Clin Oncol 2017; 35:2149-56. https://doi.org/10.1200/jco.2016.70.1961

[158] Du C, Yi X, Liu W et al. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NF κB-dependent pathway. BMC Cancer 2014; 14:869. https://doi.org/10.1186/1471-2407-14-869

[159] Wang F, Wang S, Wang Z et al. Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR. J Exp Clin Cancer Res 2012; 31:65. https://doi.org/10.1186/1756-9966-31-65

[160] Xu MH, Zheng YM, Liang BG et al. Deubiquitination of CIB1 by USP14 promotes lenvatinib resistance via the PAK1-ERK1/2 axis in hepatocellular carcinoma. Int J Biol Sci 2024; 20:3269-84. https://doi.org/10.7150/ijbs.96031

[161] Hu C, Zhang M, Moses N et al. The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53. Cell Death Dis 2020; 11:328. https://doi.org/10.1038/s41419-020-2519-8

[162] Duarte HO, Rodrigues JG, Gomes C et al. ST6Gal1 targets the ectodomain of ErbB2 in a site-specific manner and regulates gastric cancer cell sensitivity to trastuzumab. Oncogene 2021; 40:3719-33. https://doi.org/10.1038/s41388-021-01801-w

[163] Petrioli R, Licchetta A, Roviello G et al. CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab. Cancer Invest 2012; 30:65-71. https://doi.org/10.3109/07357907.2011.629380

[164] Chang X, Ye X, Dong L et al. Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma. Int J Gynecol Cancer 2011; 21:852-8. https://doi.org/10.1097/IGC.0b013e31821a3726

[165] Hires M, Jane E, Kalavska K et al. Glycan signatures for the identification of cisplatin-resistant testicular cancer cell lines: specific glycoprofiling of human chorionic gonadotropin (hCG). Cancer Med 2022; 11:968-82. https://doi.org/10.1002/cam4.4515

[166] Bast RCJr, Ravdin P, Hayes DF et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19:1865-78. https://doi.org/10.1200/jco.2001.19.6.1865

[167] Tampellini M, Berruti A, Bitossi R et al. Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients. Breast Cancer Res Treat 2006; 98:241-8. https://doi.org/10.1007/s10549-005-9155-y

[168] Carter AM, Tan C, Pozo K et al. Phosphoprotein-based biomarkers as predictors for cancer therapy. Proc Natl Acad Sci USA 2020; 117:18401-11. https://doi.org/10.1073/pnas.2010103117

[169] Eickelschulte S, Kaczorowski A, Janke F et al. Digital spatial profiling identifies phospho-JNK as a biomarker for early risk stratification of aggressive prostate cancer. Front Oncol 2025; 15:1572299. https://doi.org/10.3389/fonc.2025.1572299

[170] Naohiro N, Katsunori Y, Rinako T et al. Phospho-Smad3 signaling is predictive biomarker for hepatocellular carcinoma risk assessment in primar y biliar y cholangitis patients. Front Biosci (Landmark Ed) 2021; 26:1480-92. https://doi.org/10.52586/5042

[171] Shaw AT, Yeap BY, Mino-Kenudson M et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27:4247-53. https://doi.org/10.1200/JCO.2009.22.6993

[172] Zhang N, Meng Y, Mao S et al. FBXO31-mediated ubiquitination of OGT maintains O-GlcNAcylation homeostasis to restrain endometrial malignancy. Nat Commun 2025; 16:1274. https://doi.org/10.1038/s41467-025-56633-z

[173] Gao S, Zhang W, Yan N et al. The impact of STAT3 and phospho-STAT3 expression on the prognosis and clinicopathology of ovarian cancer: a systematic review and metaanalysis. J Ovarian Res 2021; 14:164. https://doi.org/10.1186/s13048-021-00918-6

[174] Liu Y, Chen H, Bao H et al. Comprehensive characterization of FBXW7 mutational and clinicopathological profiles in human colorectal cancers. Front Oncol 2023; 13:1154432. https://doi.org/10.3389/fonc.2023.1154432

[175] Li D, Cai Q, Li L et al. Novel post-translational modifications in cancer. Oncology 2024; 27:3-14. https://doi.org/10.1515/oncologie-2024-0533

[176] Mullard A. FDA approves 100th small-molecule kinase inhibitor. Nat Rev Drug Discov 2025; 24:891-5. https://doi.org/10.1038/d41573-025-00188-7

[177] Dai W, Qiao X, Fang Y et al. Epigenetics-targeted drugs: current paradigms and future challenges. Sig Transduct Target Ther 2024; 9:332. https://doi.org/10.1038/s41392-024-02039-0

[178] Kazandjian D, Blumenthal GM, Yuan W et al. FDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer. Clin Cancer Res 2016; 22:1307-12. https://doi.org/10.1158/1078-0432.CCR-15-2266.

[179] Shepherd FA, Pereira JR, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-32. https://doi.org/10.1056/NEJMoa050753

[180] Dungo RT, Keating GM. Afatinib: first global approval. Drugs 2013; 73:1503-15. https://doi.org/10.1007/s40265-013-0111-6

[181] Greig SL. Osimertinib: first global approval. Drugs 2016; 76:263-73. https://doi.org/10.1007/s40265-015-0533-4

[182] Malik SM, Maher VE, Bijwaard KE et al. US Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clin Cancer Res 2014; 20:2029-34. https://doi.org/10.1158/1078-0432.CCR-13-3077

[183] Larkins E, Blumenthal GM, Chen H et al. FDA approval: alectinib for the treatment of metastatic, ALK-positive non- small cell lung cancer following crizotinib. Clin Cancer Res 2016; 22:5171-6. https://doi.org/10.1158/1078-0432.CCR-16-1293

[184] Markham A. Brigatinib: first global approval. Drugs 2017; 77:1131-5. https://doi.org/10.1007/s40265-017-0776-3

[185] Khozin S, Blumenthal GM, Zhang L et al. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Clin Cancer Res 2015; 21:2436-9. https://doi.org/10.1158/1078-0432.CCR-14-3157

[186] Syed YY. Lorlatinib: first global approval. Drugs 2019; 79:93-8. https://doi.org/10.1007/s40265-018-1041-0

[187] Agrawal T. Efficacy and safety of ensartinib in the treatment of non-small cell lung cancer: a systematic review of clinical trials. J Oncol Pharm Pract 2025;10781552251387058. https://doi.org/10.1177/10781552251387058

[188] Odogwu L, Mathieu L, Blumenthal G et al. FDA approval summary: dabrafenib and trametinib for the treatment of metastatic non-small cell lung cancers harboring BRAF V600E mutations. Oncologist 2018; 23:740-5. https://doi.org/10.1634/theoncologist.2017-0642

[189] Mehta GU, Vellanki PJ, Ren Y et al. FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations. Oncologist 2024; 29:667-71. https://doi.org/10.1093/oncolo/oyae151

[190] Lee A. Zongertinib: first approval. Drugs 2026; 86:397-401. https://doi.org/10.1007/s40265-025-02265-y

[191] Awad MM, Le Bruchec Y, Lu B et al. Selective histone deacetylase inhibitor ACY-241 (citarinostat) plus nivolumab in advanced non-small cell lung cancer: results from a phase Ib study. Front Oncol 2021; 11:696512. https://doi.org/10.3389/fonc.2021.696512

[192] Gettinger S, Goldberg S, Chiang A et al. MA15. 07 NC318, an anti-siglec-15 humanized mAb, alone and in combination with pembrolizumab in immunotherapy pretreated NSCLC. J Thorac Oncol 2023; 18:S155. https://doi.org/10.1016/j.jtho.2023.09.224

[193] Wu X, Chan L, Zhu D et al. Mitosis targeting in non-small lung cancer cells by inhibition of PAD4. Heliyon 2024; 10:e27313. https://doi.org/10.1016/j.heliyon.2024.e27313

[194] Zauderer MG, Szlosarek PW, Le Moulec S et al. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1- inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. Lancet Oncol 2022; 23:758-67. https://doi.org/10.1016/s1470-2045(22)00277-7

[195] Cao J, Chen G, Qiu L et al. Efficacy and safety of tazemetostat, an EZH 2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 study. eClinicalMedicine 2025; 87:103399. https://doi.org/10.1016/j.eclinm.2025.103399

[196] Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination with Topotecan and Pembrolizumab in Recurrent Small Cell Lung Cancer. ClinicalTrials.gov [Internet]. 2022 Apr 29 [updated 2026 Apr 13]. https://clinicaltrials.gov/study/NCT05353439.

[197] Hanrahan AJ, Chen Z, Rosen N et al. BRAF-a tumouragnostic drug target with lineage-specific dependencies. Nat Rev Clin Oncol 2024; 21:224-47. https://doi.org/10.1038/s41571-023-00852-0

[198] Martínez-Gamboa DA, Kaner J. Revumenib: a new era in acute leukemia treatment. Trends Cancer 2025; 11:81-3. https://doi.org/10.1016/j.trecan.2025.01.006

[199] Wang ES, Montesinos P, Foran J et al. Ziftomenib in relapsed or refractory NPM1-mutated AML. J Clin Oncol 2025; 43:3381-90. https://doi.org/10.1200/JCO-25-01694

[200] Nicosia L, Spencer GJ, Brooks N et al. Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. Cancer Cell 2023; 41:2136-53. https://doi.org/10.1016/j.ccell.2023.11.001

[201] Van Gils N, Canales TM, Vermue E et al. The novel oral BETCBP/p300 dual inhibitor NEO2734 is highly effec tive in eradicating acute myeloid leukemia blasts and stem/progenitor cells. Hemasphere 2021; 5:e610. https://doi.org/10.1097/HS9.0000000000000610

[202] Senapati J, Muftuoglu M, Ishizawa J et al. A Phase I study of milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: clinical safety, efficacy, and correlative analysis. Blood Cancer J 2023; 13:101. https://doi.org/10.1038/s41408-023-00871-1

[203] Bewersdorf JP, Mi X, Lu B et al. Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies. Leukemia 2025; 39:765-9. https://doi.org/10.1038/s41375-025-02515-8

[204] Ochiiwa H, Ailiken G, Yokoyama M et al. TAS4464, a NEDD8- activating enzyme inhibitor, activates both intrinsic and extrinsic apoptotic pathways via c-Myc-mediated regulation in acute myeloid leukemia. Oncogene 2021; 40:1217-30. https://doi.org/10.1038/s41388-020-01586-4

[205] Elkinson S, Mccormack PL. Pomalidomide: first global approval. Drugs 2013; 73:595-604. https://doi.org/10.1007/s40265-013-0047-x

[206] Raedler LA. Revlimid (lenalidomide) now FDA approved as first-line therapy for patients with multiple myeloma. Am Health Drug Benefits 2016; 9:140-3. https://www.jhoponline.com/

[207] Palumbo A, Facon T, Sonneveld P et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008; 111:3968-77. https://doi.org/10.1182/blood-2007-10-117457

[208] Lonial S, Popat R, Hulin C et al. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial. Lancet Haematol 2022; 9:e822-32. https://doi.org/10.1016/s2352-3026(22)00290-3

[209] Hartley-Brown MA, Mo CC, Nadeem O et al. Mezigdomide-a novel cereblon E3 ligase modulator under investigation in relapsed/ refractory multiple myeloma. Cancers 2024; 16:1166. https://doi.org/10.3390/cancers16061166

[210] Raje N, Chau I, Hyman DM et al. Vemurafenib in patients with relapsed refractory multiple myeloma harboring BRAF (V600) mutations: a cohort of the histology-independent VEBASKET study. JCO Precis Oncol 2018; 2:1. https://doi.org/10.1200/po.18.00070

[211] Giesen N, Chatterjee M, Scheid C et al. A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma. Blood 2023; 141:1685-90. https://doi.org/10.1182/blood.2022017789

[212] Lunghi P, Giuliani N, Mazzera L et al. Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood 2008; 112:2450-62. https://doi.org/10.1182/blood-2007-10-114348

[213] Niesvizky R, Ely S, Mark T et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 2011; 117:336-42. https://doi.org/10.1002/cncr.25584

[214] Corradini S, Arsalani S, Maksimos M et al. Investigating the therapeutic potential of the novel CBP/p 300 protein degrader CBPD409 in multiple myeloma. Blood 2024; 144:5828. https://doi.org/10.1182/blood-2024-209620

[215] Nguyen HP, Liu E, Walker BA et al. Synergistic effects of type I PRMT1 and Type II PRMT 5 inhibitors against multiple myeloma. Blood 2023; 142:6593. https://doi.org/10.1182/blood-2023-173852

[216] Jiang L, He Q, Chen X et al. Inhibition of proteasomal deubiquitinases USP14 and UCHL 5 overcomes tyrosine kinase inhibitor resistance in chronic myeloid leukaemia. Clin Transl Med 2022; 12:e1038. https://doi.org/10.1002/ctm2.1038

[217] Chen X, Shi X, Zhao C et al. Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and-independent mechanisms. Oncotarget 2014; 5:9118-32. https://doi.org/10.18632/oncotarget.2361

[218] Mann BS, Johnson JR, Cohen MH et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12:1247-52. https://doi.org/10.1634/theoncologist.12-10-1247

[219] Vandermolen KM, Mcculloch W, Pearce CJ et al. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot 2011; 64:525-31. https://doi.org/10.1038/ja.2011.35

[220] Lee H-Z, Kwitkowski VE, Del Valle PL et al. FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Clin Cancer Res 2015; 21:2666-70. https://doi.org/10.1158/1078-0432.CCR-14-3119

[221] Shi Y, Jia B, Xu W et al. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. J Hematol Oncol 2017; 10:69. https://doi.org/10.1186/s13045-017-0439-6

[222] Chen X, Xie L, Zhu J et al. Real-world efficacy of chidamide plus R-CHOP in newly diagnosed doubleexpressor diffuse large B-cell lymphoma. Ther Adv Hematol 2024; 15:20406207241292446. https://doi.org/10.1177/20406207241292446

[223] Lin J, Huang Z, Cai Z et al. Tucidinostat plus pediatricinspired chemotherapy for newly diagnosed adult ETPALL/ LBL: a single-arm, phase 2 trial. J Hematol Oncol 2024; 17:101. https://doi.org/10.1186/s13045-024-01624-8

[224] Fornasier G, Francescon S, Baldo P. An update of efficacy and safety of cetuximab in metastatic colorectal cancer: a narrative review. Adv Ther 2018; 35:1497-509. https://doi.org/10.1007/s12325-018-0791-0

[225] Tabernero J, Grothey A, Van Cutsem E et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J Clin Oncol 2021; 39:273-84. https://doi.org/10.1200/JCO.20.02088

[226] Buzard B, Douglass L, Gustafson B et al. Response to osimertinib in a colorectal cancer patient with an EGFR T790M mutation: a case report. World J Gastrointest Oncol 2023; 15:1829-34. https://doi.org/10.4251/wjgo.v15.i10.1829

[227] Ni W, Mo H, Liu Y et al. Targeting cholesterol biosynthesis promotes anti-tumor immunity by inhibiting long noncoding RNA SNHG29-mediated YAP activation. Mol Ther 2021; 29:2995-3010. https://doi.org/10.1016/j.ymthe.2021.05.012

[228] Brana I, Shapiro G, Johnson ML et al. Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors. J Clin Oncol 2021; 39:3005. https://doi.org/10.1200/JCO.2021.39.15_suppl.3005

[229] Kuang C, Cai M, Risnik D et al. Abstract 1763: NEO2734, a novel dual bromodomain and histone acetyltransferase inhibitor, in the treatment of colorectal cancer. Cancer Res 2020; 80:1763. https://doi.org/10.1158/1538-7445.am2020-1763

[230] Dong X, Li K, Wang R et al. Targeting Skp2 by tanshinone IIA overcomes chemoresistance in colorectal cancer. Cell Biol Toxicol 2025; 41:135. https://doi.org/10.1007/s10565-025-10084-w

[231] An T, Gong Y, Li X et al. USP7 inhibitor P5091 inhibits Wnt signaling and colorectal tumor growth. Biochem Pharmacol 2017; 131:29-39. https://doi.org/10.1016/j.bcp.2017.02.011

[232] Tan X, Zhang Z, Liu P et al. RETRACTED ARTICLE: inhibition of EZH2 enhances the therapeutic effec t of 5-FU via PUMA upregulation in colorectal cancer. Cell Death Dis 2020; 11:1061. https://doi.org/10.1038/s41419-020-03266-3

[233] Wang M, Zhang Z, Chen M et al. FDW028, a novel FUT8 inhibitor, impels lysosomal proteolysis of B7- H3 via chaperone-mediated autophagy pathway and exhibits potent efficacy against metastatic colorectal cancer. Cell Death Dis 2023; 14:495. https://doi.org/10.1038/s41419-023-06027-0

[234] Yin Y, Liang Z, Li B et al. Embryonic ectoderm development (EED) inhibitor APG-5918 overcomes immunomodulatory drug (IMiD) resistance as monotherapy and synergizes with IMiDs/cereblon E3 ligase modulators (CELMoDs) in preclinical models of multiple myeloma (MM). Blood 2025; 146:1528. https://doi.org/10.1182/blood-2025-1528

[235] Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial. The Lancet 2010; 376:687-97. https://doi.org/10.1016/s0140-6736(10)61121-x

[236] Zhu T, Zou X, Yang C et al. Neutrophil extracellular traps promote gastric cancer metastasis by inducing epithelial-mesenchymal transition. Int J Mol Med 2021; 48:127. https://doi.org/10.3892/ijmm.2021.4960

[237] Yu Z, Jiang X, Qin L et al. A novel UBE2T inhibitor suppresses Wnt/ β-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination. Oncogene 2021; 40:1027-42. https://doi.org/10.1038/s41388-020-01572-w

[238] Huang X, Yi N, Zhu P et al. Sorafenib-induced macrophage extracellular traps via ARHGDIG/IL4/PADI4 axis confer drug resistance through inhibiting ferroptosis in hepatocellular carcinoma. Biol Direct 2024; 19:110. https://doi.org/10.1186/s13062-024-00560-4

[239] Yi N, Zhang L, Huang X et al. Lenvatinib-activated NDUFA4L2/ IL33/PADI4 pathway induces neutrophil extracellular traps that inhibit cuproptosis in hepatocellular carcinoma. Cell Oncol 2025; 48:487-504. https://doi.org/10.1007/s13402-024-01013-w

[240] Gautam J, Wu J, Lally JSV et al. ACLY inhibition promotes tumour immunity and suppresses liver cancer. Nature 2025; 645:507-17. https://doi.org/10.1038/s41586-025-09297-0

[241] Lu J, Wu H, Zhan P et al. PSMD14-mediated deubiquitination of CARM1 facilitates the proliferation and metastasis of hepatocellular carcinoma by inducing the transcriptional activation of FERMT1. Cell Death Dis 2025; 16:141. https://doi.org/10.1038/s41419-025-07416-3

[242] Gu M, Toh TB, Hooi L et al. Nanodiamond-mediated delivery of a G9a inhibitor for hepatocellular carcinoma therapy. ACS Appl Mater Interfaces 2019; 11:45427-41. https://doi.org/10.1021/acsami.9b16323

[243] Namgung Y, Kim SY, Kim I. Down-regulation of survivin by BIX-01294 pretreatment overcomes resistance of hepatocellular carcinoma cells to TRAIL. Anticancer Res 2019; 39:3571-8. https://doi.org/10.21873/anticanres.13503

[244] Ding Q, Cai J, Jin L et al. A novel small molecule ZYZ384 targeting SMYD3 for hepatocellular carcinoma via reducing H3K4 trimethylation of the Rac1 promoter. MedComm 2024; 5:e711. https://doi.org/10.1002/mco2.711

[245] Chiba T, Saito T, Yuki K et al. Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma. Int J Cancer 2015; 136:289-98. https://doi.org/10.1002/ijc.28985

[246] Uysal-Onganer P, D’alessio S, Mortoglou M et al. Peptidylarginine deiminase inhibitor application, using Cl-amidine, PAD2, PAD3 and PAD4 isozyme-specific inhibitors in pancreatic cancer cells, reveals roles for PAD2 and PAD3 in cancer invasion and modulation of extracellular vesicle signatures. Int J Mol Sci 2021; 22:1396. https://doi.org/10.3390/ijms22031396

[247] Umemura K, Akiyama Y, Shimada S et al. PAD2-mediated histone citrullination drives tumor progression by enhancing cell proliferation and modifying the microenvironment in pancreatic cancer. Mol Cancer Res 2025; 23:844-58. https://doi.org/10.1158/1541-7786.Mcr-24-1095

[248] Petrova E, Matevossian A, Resh MD. Hedgehog acyltransferase as a target in pancreatic ductal adenocarcinoma. Oncogene 2015; 34:263-8. https://doi.org/10.1038/onc.2013.575

[249] Petrova E, Rios-Esteves J, Ouerfelli O et al. Inhibitors of hedgehog acyltransferase block sonic hedgehog signaling. Nat Chem Biol 2013; 9:247-9. https://doi.org/10.1038/nchembio.1184

[250] Yang Y, Cao L, Guo Z et al. Deubiquitinase UCHL5 stabilizes ELK3 to potentiate cancer stemness and tumor progression in pancreatic adenocarcinoma (PAAD). Exp Cell Res 2022; 421:113402. https://doi.org/10.1016/j.yexcr.2022.113402

[251] Rios Perez MV, Roife D, Dai B et al. Antineoplastic effects of auranofin in human pancreatic adenocarcinoma preclinical models. Surg Open Sci 2019; 1:56-63. https://doi.org/10.1016/j.sopen.2019.05.004

[252] Huang F, Li C, Chen Y et al. Succinate dehydrogenase B palmitoylation promotes T cell exhaustion through the H3K27ac-PD1 axis in pancreatic cancer. Cancer Lett 2026; 642:218277. https://doi.org/10.1016/j.canlet.2026.218277

[253] Wedam S, Fashoyin-Aje L, Gao X et al. FDA approval summary: ado-trastuzumab emtansine for the adjuvant treatment of HER2-positive early breast cancer. Clin Cancer Res 2020; 26:4180-5. https://doi.org/10.1158/1078-0432.CCR-19-3980

[254] Blumenthal GM, Scher NS, Cortazar P et al. First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Clin Cancer Res 2013; 19:4911-6. https://doi.org/10.1158/1078-0432.Ccr-13-1212

[255] Ryan Q, Ibrahim A, Cohen MH et al. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 2008; 13:1114-9. https://doi.org/10.1634/theoncologist.2008-0816

[256] Singh H, Walker AJ, Amiri-Kordestani L et al. US food and drug administration approval: neratinib for the extended adjuvant treatment of early-stage HER2-positive breast cancer. Clin Cancer Res 2018; 24:3486-91. https://doi.org/10.1158/1078-0432.CCR-17-3628

[257] Narayan P, Prowell TM, Gao JJ et al. FDA approval summary: alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer. Clin Cancer Res 2021; 27:1842-9. https://doi.org/10.1158/1078-0432.CCR-20-3652

[258] Pelosci A. FDA approves capivasertib plus fulvestrant in advanced HR + HER2-breast cancer. Cancer Network 2023. Retrieved from https://www.cancernetwork.com.

[259] Yardley DA. Adverse event management of mTOR inhibitors during treatment of hormone receptor-positive advanced breast cancer: considerations for oncologists. Clin Breast Cancer 2014; 14:297-308. https://doi.org/10.1016/j.clbc.2014.03.002

[260] Reguera-Nuñez E, Xu P, Chow A et al. Therapeutic impact of nintedanib with paclitaxel and/or a PD-L 1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer. J Exp Clin Cancer Res 2019; 38:16. https://doi.org/10.1186/s13046-018-0999-5

[261] Li C, Du L, Ren Y et al. SKP2 promotes breast cancer tumorigenesis and radiation tolerance through PDCD4 ubiquitination. J Exp Clin Cancer Res 2019; 38:76. https://doi.org/10.1186/s13046-019-1069-3

[262] Kurani H, Razavipour SF, Harikumar KB et al. DOT1L is a novel cancer stem cell target for triple-negative breast cancer. Clin Cancer Res 2022; 28:1948-65. https://doi.org/10.1158/1078-0432.Ccr-21-1299

[263] Perabo FG, Yoo S, Chandhasin C et al. 210P TACH101, a first-in-class KDM4 inhibitor for treatment of triple-negative breast cancer. Ann Oncol 2021; 32:S450-1. https://doi.org/10.1016/j.annonc.2021.08.492

[264] Metzger E, Stepputtis SS, Strietz J et al. KDM4 inhibition targets breast cancer stem-like cells. Cancer Res 2017; 77:5900-12. https://doi.org/10.1158/0008-5472.Can-17-1754

[265] Pignata S, Oza A, Hall G et al. Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status. Br J Cancer 2025; 132:725-32. https://doi.org/10.1038/s41416-025-02966-x

[266] Moore K, Colombo N, Scambia G et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018; 379:2495-505. https://doi.org/10.1056/NEJMoa1810858

[267] González-Martín A, Pothuri B, Vergote I et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2019; 381:2391-402. https://doi.org/10.1056/NEJMoa1910962

[268] Monk BJ, Parkinson C, Lim MC et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol 2022; 40:3952-64. https://doi.org/10.1200/JCO.22.01003

[269] Bitler BG, Wu S, Park PH et al. ARID1A-mutated ovarian cancers depend on HDAC6 activity. Nat Cell Biol 2017; 19:962-73. https://doi.org/10.1038/ncb3582

[270] Lee EK, Tan-Wasielewski Z, Matulonis UA et al. Results of an abbreviated phase Ib study of the HDAC 6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol Rep 2019; 29:118-22. https://doi.org/10.1016/j.gore.2019.07.010

[271] Yoo J, Jeon YH, Lee DH et al. HDAC6-selective inhibitors enhance anticancer effects of paclitaxel in ovarian cancer cells. Oncol Lett 2021; 21:201. https://doi.org/10.3892/ol.2021.12462

[272] Kim JY, Han SY, Yoo J et al. HDAC8-selective inhibition by PCI- 34051 enhances the anticancer effec t s of A CY-241 in ovarian cancer cells. Int J Mol Sci 2022; 23:8645. https://doi.org/10.3390/ijms23158645

[273] Guruvaiah P, Chava S, Sun CW et al. ATAD2 is a driver and a therapeutic target in ovarian cancer that functions by upregulating CENPE. Cell Death Dis 2023; 14:456. https://doi.org/10.1038/s41419-023-05993-9

[274] Wada M, Kukita A, Sone K et al. Epigenetic modifier SETD8 as a therapeutic target for high-grade serous ovarian cancer. Biomolecules 2020; 10:1686. https://doi.org/10.3390/biom10121686

[275] Chava S, Bugide S, Edwards YJK et al. Disruptor of telomeric silencing 1-like promotes ovarian cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis. Oncogenesis 2021; 10:48. https://doi.org/10.1038/s41389-021-00339-6

[276] Corr BR, Moroney MR, Woodruff E et al. Combination CDC-like kinase inhibition (CLK)/Dual-specificity tyrosineregulated kinase (DYRK) and taxane therapy in CTNNB1- mutated endometrial cancer. 2023. bioRxiv, https://pubmed.ncbi.nlm.nih.gov/37066339/, 6 April 2023, preprint: not peer reviewed.

[277] Huang P, Almeciga-Pinto I, Jarpe M et al. Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models. Oncotarget 2017; 8:2694-707. https://doi.org/10.18632/oncotarget.13738

[278] Chen Z, Wang M, Wu D et al. Discovery of CBPD-409 and CBPD-268 as highly potent and orally efficacious CBP/p 300 PROTAC degraders for the treatment of castration-resistant prostate cancer. Cancer Res 2024; 84:4504. https://doi.org/10.1158/1538-7445.AM2024-4504.

[279] Chen L, Zhang J, Liu W et al. HKI-357 inhibits castrationresistant prostate cancer by targeting UBE2C via the AKT signaling pathway. Biochem Pharmacol 2025; 242:117410. https://doi.org/10.1016/j.bcp.2025.117410

[280] Zhang Y, Su M, Chen Y et al. EHMT2-mediated R-loop formation promotes the malignant progression of prostate cancer via activating Aurora B. Clin Transl Med 2025; 15:e70164. https://doi.org/10.1002/ctm2.70164

[281] Smith T, White T, Chen Z et al. The KDM5 inhibitor PBIT reduces proliferation of castration-resistant prostate cancer cells via cell cycle arrest and the induction of senescence. Exp Cell Res 2024; 437:113991. https://doi.org/10.1016/j.yexcr.2024.113991

[282] Loriot Y, Necchi A, Park Se H et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med 2019; 381:338-48. https://doi.org/10.1056/NEJMoa1817323

[283] Zhang X, Chen Z, He X et al. SUMOylation of SETD8 promotes tumor growth by methylating and stabilizing MYC in bladder cancer. Adv Sci 2025; 12:e2501734. https://doi.org/10.1002/advs.202501734

[284] Wang S, Klein SO, Urban S et al. Structure-guided design of a selective inhibitor of the methyltransferase KMT 9 with cellular activity. Nat Commun 2024; 15:43. https://doi.org/10.1038/s41467-023-44243-6

[285] Deeks ED. Belzutifan: first approval. Drugs 2021; 81:1921-7. https://doi.org/10.1007/s40265-021-01606-x

[286] Tu R, Ma J, Chen Y et al. USP7 depletion potentiates HIF2 α degradation and inhibits clear cell renal cell carcinoma progression. Cell Death Dis 2024; 15:749. https://doi.org/10.1038/s41419-024-07136-0

[287] Specenier P, Vermorken JB. Cetuximab: its unique place in head and neck cancer treatment. Biologics 2013; 7:77-90. https://doi.org/10.2147/BTT.S43628

[288] Zhang W, Cheng J, Diao P et al. Therapeutically targeting head and neck squamous cell carcinoma through synergistic inhibition of LSD1 and JMJD3 by TCP and GSK-J1. Br J Cancer 2020; 122:528-38. https://doi.org/10.1038/s41416-019-0680-6

[289] Ho AL, Brana I, Haddad R et al. Tipifarnib in head and neck squamous cell carcinoma with HRAS mutations. J Clin Oncol 2021; 39:1856-64. https://doi.org/10.1200/jco.20.02903

[290] Li M, Sun F, Wang J et al. SUV39H1 epigenetically modulates the MCPIP1-AURKA signaling axis to enhance neuroblastoma tumorigenesis. Oncogene 2024; 43:3306-20. https://doi.org/10.1038/s41388-024-03164-4

[291] Sangha R, Jamal R, Spratlin J et al. A first-in-human phase I trial of daily oral zelenirstat, a N-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomas. Invest New Drugs 2024; 42:386-93. https://doi.org/10.1007/s10637-024-01448-w

[292] Therachiyil L, Surendranath A, Anand A et al. Proteomicsdriven cancer biomarkers for early detection and targeted therapy: insights from the Middle East. J Proteome Res 2026; 25:21-40. https://doi.org/10.1021/acs.jproteome.5c00949

[293] Yu J, Gui X, Zou Y et al. A proteogenomic analysis of cervical cancer reveals therapeutic and biological insights. Nat Commun 2024; 15:10114. https://doi.org/10.1038/s41467-024-53830-0

[294] Abelin JG, Bergstrom EJ, Rivera KD et al. Workflow enabling deepscale immunopeptidome, proteome, ubiquitylome, phosphoproteome, and acetylome analyses of sample-limited tissues. Nat Commun 2023; 14:1851. https://doi.org/10.1038/s41467-023-37547-0.

[295] Hu B, He R, Pang K et al. High-resolution spatially resolved proteomics of complex tissues based on microfluidics and transfer learning. Cell 2025; 188:734-48. https://doi.org/10.1016/j.cell.2024.12.023

[296] Makhmut A, Qin D, Fritzsche S et al. A framework for ultralow- input spatial tissue proteomics. Cell Syst 2023; 14:1002-14. https://doi.org/10.1016/j.cels.2023.10.003

[297] Mund A, Coscia F, Kriston A et al. Deep visual proteomics defines single-cell identity and heterogeneity. Nat Biotechnol 2022; 40:1231-40. https://doi.org/10.1038/s41587-022-01302-5

[298] Keren L, Bosse M, Thompson S et al. MIBI-TOF: a multiplexed imaging platform relates cellular phenotypes and tissue structure. Sci Adv 2019; 5:eaax5851. https://doi.org/10.1126/sciadv.aax5851

[299] Xiao X, Hu M, Gao L et al. Low-input redoxomics facilitates global identification of metabolic regulators of oxidative stress in the gut. Sig Transduct Target Ther 2025; 10:8. https://doi.org/10.1038/s41392-024-02094-7

[300] Abbatiello SE, Schilling B, Mani D et al. Large-scale interlaboratory study to develop, analytically validate and apply highly multiplexed, quantitative peptide assays to measure cancer-relevant proteins in plasma. Mol Cell Proteomics 2015; 14:2357-74. https://doi.org/10.1074/mcp.M114.047050

[301] Kennedy JJ, Abbatiello SE, Kim K et al. Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Nat Methods 2014; 11:149-55. https://doi.org/10.1038/NMETH.2763

[302] Babur Ö, Luna A, Korkut A et al. Causal interactions from proteomic profiles: molecular data meet pathway knowledge. Patterns 2021; 2:100257. https://doi.org/10.1016/j.patter.2021.100257